The size of the Latin American in-vitro toxicology testing market is expected to worth USD 3672.35 Million by 2027 from USD 1875.83 Million in 2022, growing at a CAGR of 14.38% from 2022 to 2027.
In-vitro toxicology testing is the scientific analysis of toxic effects produced by chemical substances on cultured mammalian cells or bacteria. Toxicity testing is very essential in drug discovery as identifies the toxic effects of new compound in the early stages of drug discovery. This early detection of toxicity reduces the development cost and time.
Availability of numerous animal welfare organizations that maintain the reduced utilization of animals for pre-clinical studies, rising investment in research & development to enhance the research in cell culture, increasing number of aging population, growing demand for healthy lifestyle are driving the growth of in-vitro toxicology testing market in Latin America. However, unawareness of advanced toxicology testing procedures and inadequate facilities (such as social & economic factors) for the advancements of new research technologies are restraining the growth of in-vitro toxicology testing market in Latin America.
This research report on the Latin America In-Vitro Toxicology Testing Market has been segmented and sub-segmented into the following categories:
By Toxicity Endpoints & Tests
Notable companies in the Latin America In-Vitro Toxicology Testing Market are Covance, Inc. (A subsidiary of LabCorp) (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Eurofins Scientific SE (Luxembourg), General Electric Company (U.S.), BioReliance, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Catalent (U.S.) and Cyprotex (U.K.).
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org